Imatinib Mesylate In The Treatment Of Newly Diagnosed Or Refractory/Resistant C-Kit Positive Acute Myeloid Leukemia. Results Of An Italian Multicentric Phase Ii Study

Pier Paolo Piccaluga,Michele Malagola,Michela Rondoni,Mario Arpinati,Stefania Paolini,Anna Candoni,Renato Fanin,Emanuela Messa,Maria Teresa Pirrotta,Francesco Lauria,Giuseppe Visani,Daniele Alberti,Francesca Rancati,Vincenza Vinaccia,Domenico Russo,Giuseppe Saglio,Michele Baccarani,Giovanni Martinelli

HAEMATOLOGICA（2007）

引用 23|浏览17

暂无评分

摘要

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

查看译文

关键词

imatinib mesylate, acute myeloid leukemia, c-KIT, PDGFRB, targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要